If you used Ozempic or a similar GLP-1 medication and experienced a severe gastrointestinal injury, you may qualify for compensation.
Lawsuits allege that GLP-1 medications like Ozempic and similar drugs (semaglutide-based, used for diabetes and weight loss) caused severe gastrointestinal injuries — including gastroparesis (stomach paralysis), intestinal obstruction, and related complications — without adequate warning to patients and doctors.
The FDA added an ileus (intestinal obstruction) warning to Ozempic's label in January 2025, after the litigation was already underway.
Here's what happens after you reach out:
A short set of free eligibility questions about your situation — takes about two minutes.
Our network reviews your answers against current qualifying criteria and reaches out if you may qualify.
You decide whether to move forward. There's never a cost to check your eligibility.
Nearly 3,850 lawsuits are consolidated in MDL 3094 before Judge Karen Marston in the Eastern District of Pennsylvania. The litigation remains in its early stages — no trials or settlements have occurred as of July 2026. A status conference held June 23, 2026 moved the case toward expert-witness and summary-judgment phases, with bellwether trial selection expected in late 2026.
A new federal MDL now consolidates lawsuits claiming Ozempic and other GLP-1 drugs caused NAION, a rare form of sudden vision loss, in a track separate from existing gastroparesis claims.
Read more →The judge overseeing the Ozempic gastroparesis MDL ruled that claims must be backed by an objective gastric emptying study, not just reported symptoms, raising the evidentiary bar litigation-wide.
Read more →The FDA revised Ozempic's prescribing label in January 2025 to warn about severe gastrointestinal adverse reactions, though plaintiffs' attorneys say it still doesn't fully warn of gastroparesis risk.
Read more →Get updates on Ozempic/GLP-1, plus other case types we cover.
We'll keep you updated on Ozempic/GLP-1 and other case types.